Amendments to the Claims

This listing of claims will replace all prior listings of claims in the application.

Listing of Claims

1. (Currently Amended) A compound of Formula (I):



(I)

wherein Z is $-CHR^9-$, $-C(O)-$, $-O-$, $-S-$, $-S(O)-$, $-SO_2-$, $-N(R^9)-$, $-C(O)N(R^9)-$, or $-N(R^9)C(O)-$;

l is 1 or 2;

m is 0, 1 or 2;

n is 1 or 2;

with the proviso that when n is 1, Z cannot be -O- or -S-;

R^1 and R^2 are each independently hydrogen, C_{1-6}alkyl, C_{3-6}cycloalkyl, or (C_{3-6}cycloalkyl)C_{1-6}alkyl; provided that R^1 and R^2 are not both hydrogen;

R^3 is hydrogen or C_{1-6}alkyl;

R^4, R^5, and R^9 are independently hydrogen, C_{1-6}alkyl or arylC_{1-6}alkylene;

R^6, R^7, and R^8 are independently hydrogen, fluoro, chloro, bromo, CF_3, $-OCF_3$, $-N(R^{10})_2$, C_{1-6}alkyl, C_{1-6}alkoxy, heteroaryl or aryl;

each R^{10} is independently hydrogen, or $-C_{1-6}$alkyl;

wherein any C_{1-6}alkyl, C_{1-6}alkylene, or C_{1-6}alkoxy of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is optionally partially unsaturated;

wherein any heteroaryl or aryl is optionally substituted with one or two substituents independently selected from halo, $-CF_3$, $-OCF_3$, C_{1-6}alkoxy, $-N(R^{10})_2$, and C_{1-6}alkyl;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1, wherein R^1 is hydrogen.

3. (Original) The compound of claim 1, wherein R^1 is C_{1-6}alkyl, C_{3-6}cycloalkyl, or (C_{3-6}cycloalkyl)C_{1-6}alkyl.

4. (Original) The compound of claim 1, wherein R^1 is C_{2-6}alkyl, C_{3-6}cycloalkyl, or (C_{3-6}cycloalkyl)C_{1-6}alkyl.

5. (Original) The compound of claim 1, wherein R^1 is C_{3-6}alkyl, C_{3-6}cycloalkyl, or (C_{3-6}cycloalkyl)C_{1-6}alkyl.

6. (Original) The compound of claim 1, wherein R^1 is methyl, ethyl, propyl, isopropyl, or cyclopropylmethyl.

7. (Original) The compound of claim 1, wherein R^1 is ethyl, propyl, isopropyl, or cyclopropylmethyl.

8. (Original) The compound of claim 1, wherein R^1 is propyl, isopropyl, or cyclopropylmethyl.

9. (Original) The compound of claim 1, wherein R^2 is hydrogen.

10. (Original) The compound of claim 1, wherein R^2 is C_{1-6}alkyl, C_{3-6}cycloalkyl, or (C_{3-6}cycloalkyl)C_{1-6}alkyl.

11. (Original) The compound of claim 1, wherein R^2 is C_{2-6}alkyl, C_{3-6}cycloalkyl, or (C_{3-6}cycloalkyl)C_{1-6}alkyl.

12. (Original) The compound of claim 1, wherein R^2 is C_{3-6}alkyl, C_{3-6}cycloalkyl, or (C_{3-6}cycloalkyl)C_{1-6}alkyl.

13. (Original) The compound of claim 1, wherein R^2 is methyl, ethyl, propyl, isopropyl, or cyclopropylmethyl.

14. (Original) The compound of claim 1, wherein R^2 is ethyl, propyl, isopropyl, or cyclopropylmethyl.

15. (Original) The compound of claim 1, wherein R^2 is propyl, isopropyl, or cyclopropylmethyl.

16. (Original) The compound of claim 10, wherein R^1 is hydrogen.

17. (Original) The compound of claim 1, wherein R^1 is C_{2-3}alkyl and R^2 is hydrogen, or C_{2-6}alkyl.

18. (Original) The compound of claim 1, wherein R^1 is hydrogen, or C_{2-3}alkyl; and R^2 is C_{2-6}alkyl.

19. (Original) The compound of claim 1, wherein R^1 is C_{2-3}alkyl and R^2 is C_{2-6}alkyl.

20. (Original) The compound of claim 1, wherein R^1 is ethyl or propyl and R^2 is ethyl, propyl or butyl.

21. (Original) The compound of claim 1, wherein R^3 is hydrogen.

22. (Original) The compound of claim 1, wherein R^3 is C_{1-6}alkyl.

23. (Original) The compound of claim 23, wherein; and R^3 is methyl, ethyl, propyl, or butyl.

24. (Original) The compound of claim 23, wherein; and R^3 is methyl or ethyl.

25. (Original) The compound of claim 1, wherein R^4 and R^5 are independently hydrogen, methyl, ethyl, propyl, butyl, 2-phenylethyl, or benzyl.

26. (Original) The compound of claim 25, wherein R^4 and R^5 are independently hydrogen, methyl, ethyl, propyl, or benzyl.

27. (Original) The compound of claim 25, wherein R^4 and R^5 are independently methyl, ethyl, or benzyl.

28. (Original) The compound of claim 1, wherein R^6, R^7, or R^8 is phenyl optionally substituted with one or two substituents independently selected from halo, $-CF_3$, $-OCF_3$, C_{1-6}alkoxy, $-N(R^{10})_2$, and C_{1-6}alkyl.

29. (Original) The compound of claim 28, wherein R^6, R^7, or R^8 is phenyl optionally substituted with one or two substituents independently selected from fluoro, chloro, bromo, $-CF_3$, $-OCF_3$, C_{1-6}alkoxy and $-N(R^{10})_2$.

30. (Original) The compound of claim 28, wherein R^6, R^7, or R^8 is phenyl optionally substituted with one or two substituents independently selected from fluoro, chloro, and bromo.

31. (Original) The compound of claim 28, wherein R^6 is 2,4-dichlorophenyl or 2,6-difluorophenyl.

32. (Original) The compound of claim 28, wherein R^7 is 2,4-dichlorophenyl or 2,6-difluorophenyl.

33. (Original) The compound of claim 28, wherein R^8 is 2,4-dichlorophenyl or 2,6-difluorophenyl.

34. (Cancelled)

35. (Cancelled)

36. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

37.-41. (Cancelled)

42. (Currently Amended) A method for treating a disease or condition in a mammal in need thereof wherein the ~~5-HT~~5-HT_{2C} receptor is implicated and modulation of ~~5-HT~~5-HT_{2C} function is desired comprising administering a therapeutically effective amount of a compound of claim 1 to the mammal.

43. (Currently Amended) The method of claim 42, wherein the disease is selected from the group consisting of anxiety, obesity, depression, ~~or a stress related disease~~obsessive compulsive disorder, panic disorder, phobias, psychiatric syndrome and migraine headache.

44. (Cancelled).

45. (Currently Amended) A compound of Formula (II):



(II)

wherein Z is -CHR^9-, -C(O)-, -O-, -S-, -S(O)-, -SO$_2$-, -N(R^9)-, -C(O)N(R^9)-, or -N(R^9)C(O)-;

l is 1 or 2;

m is 0, 1 or 2;

n is 1 or 2;

with the proviso that when n is 1, Z cannot be -O- or -S-,

R^1 and R^2 are each independently hydrogen, C$_{1-6}$alkyl, C$_{3-6}$cycloalkyl, or (C$_{3-6}$cycloalkyl)C$_{1-6}$alkyl; provided that R^1 and R^2 are not both hydrogen;

R^3 is -C(O)-aryl, -C(O)-heteroaryl, -C(O)-C$_{1-6}$alkyl, -C(O)-C$_{1-6}$haloalkyl, -C(O)O-C$_{1-6}$alkyl, or -C(O)O-C$_{1-6}$haloalkyl, where aryl or heteroaryl is optionally substituted with one or two halo, -CF$_3$, -OCF$_3$, C$_{1-6}$alkoxy, -N(R^{10})$_2$, or -C$_{1-6}$alkyl;

R^4, R^5, and R^9 are independently hydrogen, C$_{1-6}$alkyl or arylC$_{1-6}$alkylene;

R^6, R^7, and R^8 are independently hydrogen, fluoro, chloro, bromo, CF$_3$, -OCF$_3$, -N(R^{10})$_2$, C$_{1-6}$alkyl, C$_{1-6}$alkoxy, heteroaryl or aryl;

each R^{10} is independently hydrogen, or -C$_{1-6}$alkyl;

wherein any C$_{1-6}$alkyl, C$_{1-6}$alkylene, or C$_{1-6}$alkoxy of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, and R^{10} is optionally partially unsaturated;

wherein any heteroaryl or aryl is optionally substituted with one or two substituents independently selected from halo, $-CF_3$, $-OCF_3$, C_{1-6}alkoxy, $-N(R^{10})_2$, and C_{1-6}alkyl.

46. (Cancelled)

47. (Cancelled)